Pulmatrix (NASDAQ:PULM) Shares Pass Above 50-Day Moving Average – What’s Next?

Posted by ABMN Staff on Jun 27th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report)’s stock price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.36 and traded as high as $1.7250. Pulmatrix shares last traded at $1.64, with a volume of 27,450 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a research note on Wednesday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pulmatrix has an average rating of “Sell”.

Read Our Latest Research Report on Pulmatrix

Pulmatrix Stock Performance

The company has a market cap of $5.99 million, a PE ratio of -1.33 and a beta of 1.95. The firm has a fifty day simple moving average of $1.36 and a 200 day simple moving average of $2.04.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Pulmatrix stock. DRW Securities LLC acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is owned by institutional investors and hedge funds.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).